AgingResearch.NewsJoin free

Hanmi Pharmaceutical

CompanySouth KoreaFounded 1973

Wikidata

Hanmi Pharmaceutical develops 9 assets, the furthest approved (Efpe in obesity). Mostly peptide and small molecule acting on GLP1R, lipid and ceramide metabolism and Insulin/IGF-1 signalling; based in South Korea, founded in 1973.

9
Assets
Furthest stage
Approved
29
Trials
0
Signals

Pipeline

9

  • Efpe

    Activates GLP-1 receptors to increase glucose-dependent insulin secretion, suppress appetite, and promote weight loss.

    Approved, Peptide, GLP1R, obesity

  • efpeglenatide

    Activates GLP-1 receptors to reduce appetite and enhance glucose-dependent insulin secretion.

    Approved, Peptide, Insulin/IGF-1 signalling, GLP1R, obesity, overweight

  • Ephe

    Activates GLP-1 receptors to reduce appetite, increase satiety, and improve glucose regulation.

    Approved, Peptide, GLP1R, obesity

6 more assets

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms8
  • Trials37
  • Signals3
  • Similar companies6

Papers

Intelligence